Genetically engineered mesenchymal stem cells: Applications in spine therapy

Regenerative Medicine

Volumn 4, Issue 1, 2009, Pages 99-108

  Aslan, Hadi ^a   Sheyn, Dima ^a   Gazit, Dan ^a,b  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Back pain; Bone morphogenetic proteins; Gene therapy; Intervertebral disc; Mesenchymal stem cells; Spinal fusion

Indexed keywords

BONE MORPHOGENETIC PROTEIN; BONE MORPHOGENETIC PROTEIN 2; CALCIUM PHOSPHATE; HYDROXYAPATITE; RECOMBINANT PROTEIN;

ADIPOSE TISSUE; BONE DEVELOPMENT; BONE MASS; CELL DIFFERENTIATION; CELL REGENERATION; CELL RENEWAL; CLINICAL EFFECTIVENESS; COST EFFECTIVENESS ANALYSIS; GENE DELIVERY SYSTEM; GENETIC ENGINEERING; GENETIC RECOMBINATION; HEMATOPOIETIC STEM CELL; HUMAN; MESENCHYMAL STEM CELL; MESENCHYMAL STEM CELL TRANSPLANTATION; NONHUMAN; OSSIFICATION; PRIORITY JOURNAL; REGENERATIVE MEDICINE; REVIEW; SPINE DISEASE; SPINE FUSION; ANIMAL; BIOLOGICAL MODEL; CYTOLOGY; GENETICS; METABOLISM; METHODOLOGY; SPINE;

ANIMALS; GENETIC ENGINEERING; HUMANS; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STEM CELLS; MODELS, BIOLOGICAL; OSTEOGENESIS; REGENERATIVE MEDICINE; SPINAL DISEASES; SPINAL FUSION; SPINE;

EID: 58949095034     PISSN: 17460751     EISSN: None     Source Type: Journal    
DOI: 10.2217/17460751.4.1.99     Document Type: Review

References (91)

1. Buckwalter JA: Aging and degeneration of the human intervertebral disc. Spine 20, 1307-1314 (1995).
2. Nishida K, Kang JD, Gilbertson LG et al.: Modulation of the biologic activity of the rabbit intervertebral disc by gene therapy: an in vivo study of adenovirus-mediated transfer of the human transforming growth factor β1 encoding gene. Spine 24, 2419-2425 (1999).
3. Kraemer J: Natural course and prognosis of intervertebral disc diseases. International Society for the Study of the Lumbar Spine Seattle, Washington, June 1994. Spine 20, 635-639 (1995).
4. Khan SN, Lane JM: Spinal fusion surgery: animal models for tissue-engineered bone constructs. Biomaterials 25, 1475-1485 (2004).
5. DePalma AF, Rothman RH: The nature of pseudarthrosis. Clin. Orthop. Relat. Res. 59, 113-118 (1968).
6. Steinmann JC, Herkowitz HN: Pseudarthrosis of the spine. Clin. Orthop. Relat. Res. 80-90 (1992).
7. Conaty JP, Mongan ES: Cervical fusion in rheumatoid arthritis. J. Bone Joint Surg. Am. 63, 1218-1227 (1981).
8. Ferlic DC, Clayton ML, Leidholt JD, Gamble WE: Surgical treatment of the symptomatic unstable cervical spine in rheumatoid arthritis. J. Bone Joint Surg. Am. 57, 349-354 (1975).
9. Zoma A, Sturrock RD, Fisher WD, Freeman PA, Hamblen DL: Surgical stabilisation of the rheumatoid cervical spine. A review of indications and results. J. Bone Joint. Surg. Br. 69, 8-12 (1987).
10. Boden SD, Martin GJ Jr, Horton WC, Truss TL, Sandhu HS: Laparoscopic anterior spinal arthrodesis with rhBMP-2 in a titanium interbody threaded cage. J. Spinal Disord. 11, 95-101 (1998).
11. Boden SD, Schimandle JH, Hutton WC: 1995 Volvo Award in basic sciences. The use of an osteoinductive growth factor for lumbar spinal fusion. Part II: Study of dose, carrier, and species. Spine 20, 2633-2644 (1995).
12. Alden TD, Pittman DD, Beres EJ et al.: Percutaneous spinal fusion using bone morphogenetic protein-2 gene therapy. J. Neurosurg. 90, 109-114 (1999).
13. Louis-Ugbo J, Kim HS, Boden SD et al.: Retention of 125I-labeled recombinant human bone morphogenetic protein-2 by biphasic calcium phosphate or a composite sponge in a rabbit posterolateral spine arthrodesis model. J. Orthop. Res. 20, 1050-1059 (2002).
14. Martin GJ Jr, Boden SD, Marone MA, Marone MA, Moskovitz PA: Posterolateral intertransverse process spinal arthrodesis with rhBMP-2 in a nonhuman primate: important lessons learned regarding dose, carrier, and safety. J. Spinal Disord. 12, 179-186 (1999).
15. Yoon ST, Boden SD: Spine fusion by gene therapy. Gene Ther. 11, 360-367 (2004).
16. Gupta MC, Theerajunyaporn T, Maitra S et al.: Efficacy of mesenchymal stem cell enriched grafts in an ovine posterolateral lumbar spine model. Spine 32, 720-726 (2007).
17. Molinari RW, Gerlinger T: Functional outcomes of instrumented posterior lumbar interbody fusion in active-duty US servicemen: a comparison with nonoperative management. Spine J. 1, 215-224 (2001).
18. Odorico JS, Kaufman DS, Thomson JA: Multilineage differentiation from human embryonic stem cell lines. Stem Cells 19, 193-204 (2001).
19. Abdallah BM, Kassem M: Human mesenchymal stem cells: from basic biology to clinical applications. Gene Ther. 15, 109-116 (2008).
20. Chamberlain G, Fox J, Ashton B, Middleton J: Concise review: mesenchymal stem cells: their phenotype, differentiation capacity, immunological features, and potential for homing. Stem Cells 23, 2739-2749 (2007).
21. Labat ML: Stem cells and the promise of eternal youth: embryonic versus adult stem cells. Biomed. Pharmacother. 55, 179-185 (2001).
22. Friedenstein AJ, Gorskaja JF, Kulagina NN: Fibroblast precursors in normal and irradiated mouse hematopoietic organs. Exp. Hematol. 4, 267-274 (1976).
23. Pittenger MF, Mackay AM, Beck SC et al.: Multilineage potential of adult human mesenchymal stem cells. Science 284, 143-147 (1999).
24. Deans RJ, Moseley AB: Mesenchymal stem cells: biology and potential clinical uses. Exp. Hematol. 28, 875-884 (2000).
25. + cells. Stem Cells 24, 1728-1737 (2006).
26. Zuk PA, Zhu M, Mizuno H et al.: Multilineage cells from human adipose tissue: implications for cell-based therapies. Tissue Eng. 7, 211-228 (2001).
27. Zuk PA, Zhu M, Ashjian P et al.: Human adipose tissue is a source of multipotent stem cells. Mol. Biol. Cell. 13, 4279-4295 (2002).
28. Sheyn D, Pelled G, Zilberman Y et al.: Nonvirally engineered porcine adipose tissue-derived stem cells: use in posterior spinal fusion. Stem Cells 26, 1056-1064 (2008).
29. Sgodda M, Aurich H, Kleist S et al.: Hepatocyte differentiation of mesenchymal stem cells from rat peritoneal adipose tissue in vitro and in vivo. Exp. Cell. Res. 313, 2875-2886 (2007).
30. Yamamoto N, Akamatsu H, Hasegawa S et al.: Isolation of multipotent stem cells from mouse adipose tissue. J. Dermatol. Sci. 48, 43-52 (2007).
31. Housman TS, Lawrence N, Mellen BG et al.: The safety of liposuction: results of a national survey. Dermatol. Surg. 28, 971-978 (2002).
32. Liechty KW, MacKenzie TC, Shaaban AF et al.: Human mesenchymal stem cells engraft and demonstrate site-specific differentiation after in utero transplantation in sheep. Nat. Med. 6, 1282-1286 (2000).
33. Yamaguchi A: Regulation of differentiation pathway of skeletal mesenchymal cells in cell lines by transforming growth factor-β superfamily. Semin. Cell Biol. 6, 165-173 (1995).
34. Yamaguchi A, Ishizuya T, Kintou N et al.: Effects of BMP-2, BMP-4, and BMP-6 on osteoblastic differentiation of bone marrow-derived stromal cell lines, ST2 and MC3T3-G2/PA6. Biochem. Biophys. Res. Commun. 220, 366-371 (1996).
35. Aslan H, Ravid-Amir O, Clancy BM et al.: Advanced molecular profiling in vivo detects novel function of Dickkopf-3 in the regulation of bone formation. J. Bone Miner. Res. 21, 1935-1945 (2006).
36. Muschler GF, Nitto H, Matsukura Y et al.: Spine fusion using cell matrix composites enriched in bone marrow-derived cells. Clin. Orthop. Relat. Res. 407, 102-118 (2003).
37. Ohgushi H, Dohi Y, Katuda T et al.: In vitro bone formation by rat marrow cell culture. J. Biomed. Mater. Res. 32, 333-340 (1996).
38. Okumura M, Ohgushi H, Dohi Y et al.: Osteoblastic phenotype expression on the surface of hydroxyapatite ceramics. J. Biomed. Mater. Res. 37, 122-129 (1997).
39. Yoshikawa T, Ohgushi H, Tamai S: Immediate bone forming capability of prefabricated osteogenic hydroxyapatite. J. Biomed. Mater. Res. 32, 481-492 (1996).
40. Minamide A, Yoshida M, Kawakami M et al.: The use of cultured bone marrow cells in type I collagen gel and porous hydroxyapatite for posterolateral lumbar spine fusion. Spine 30, 1134-1138 (2005).
41. Tan KK, Tan GH, Shamsul BS et al.: Bone graft substitute using hydroxyapatite scaffold seeded with tissue engineered autologous osteoprogenitor cells in spinal fusion: early result in a sheep model. Med. J. Malaysia 60, 53-58 (2005).
42. Kruyt MC, Wilson CE, de Bruijn JD et al.: The effect of cell-based bone tissue engineering in a goat transverse process model. Biomaterials 27, 5099-5106 (2006).
43. Hamilton DK, Jones-Quaidoo SM, Sansur C et al.: Outcomes of bone morphogenetic protein-2 in mature adults: posterolateral non-instrument-assisted lumbar decompression and fusion. Surg. Neurol. 69, 457-461 (2008).
44. Lewandrowski KU, Nanson C, Calderon R: Vertebral osteolysis after posterior interbody lumbar fusion with recombinant human bone morphogenetic protein 2: a report of five cases. Spine J. 7, 609-614 (2007).
45. Lu J, Bhargav D, Wei AQ, Diwan A: Posterolateral intertransverse spinal fusion possible in osteoporotic rats with BMP-7 in a higher dose delivered on a composite carrier. Spine 33, 242-249 (2008).
46. Slosar PJ, Josey R, Reynolds J: Acclerating lumbar fusions by combinig rhBMP-2 with allograft bone: a prospective analysis of interbody fusion rates and clinical outcomes. Spine 7, 301-307 (2007).
47. Salamon ML, Althausen PL, Gupta MC, Laubach J: The effects of BMP-7 in a rat posterolateral intertransverse process fusion model. J. Spinal Disord. Tech. 16, 90-95 (2003).
48. Boden SD, Kang J, Sandhu H, Heller JG: Use of recombinant human bone morphogenetic protein-2 to achieve posterolateral lumbar spine fusion in humans: a prospective, randomized clinical pilot trial: 2002 Volvo Award in clinical studies. Spine 27, 2662-2673 (2002).
49. McClellan JW, Mulconrey DS, Forbes RJ, Fullmer N: Vertebral bone resorption after transforaminal lumbar interbody fusion with bone morphogenetic protein (rhBMP-2). J. Spinal Disord. Tech. 19, 483-486 (2006).
50. Joseph V, Rampersaud YR: Heterotopic bone formation with the use of rhBMP2 in posterior minimal access interbody fusion: a CT analysis. Spine 32, 2885-2890 (2007).
51. Wong DA, Kumar A, Jatana S, Ghiselli G, Wong K: Neurologic impairment from ectopic bone in the lumbar canal: a potential complication of off-label PLIF/TLIF use of bone morphogenetic protein-2 (BMP-2). Spine J. 8(6), 1011-1018 (2007).
52. Garrison KR, Donell S, Ryder J et al.: Clinical effectiveness and cost-effectiveness of bone morphogenetic proteins in the non-healing of fractures and spinal fusion: a systematic review. Health Technol. Assess. 11, 1-182 (2007).
53. Yoon ST, Boden SD: Spine fusion by gene therapy. Gene Ther. 11, 360-367 (2004).
54. Lu SS, Zhang X, Soo C et al.: The osteoinductive properties of Nell-1 in a rat spinal fusion model. Spine J. 7, 50-60 (2007).
55. Li JZ, Li H, Sasaki T et al.: Osteogenic potential of five different recombinant human bone morphogenetic protein adenoviral vectors in the rat. Gene Ther. 10, 1735-1743 (2003).
56. Miyazaki M, Sugiyama O, Zou J et al.: Comparison of lentiviral and adenoviral gene therapy for spinal fusion in rats. Spine 33, 1410-1417 (2008).
57. Riew KD, Lou J, Wright NM et al.: Thoracoscopic intradiscal spine fusion using a minimally invasive gene-therapy technique. J. Bone Joint Surg. Am. 85A, 866-871 (2003).
58. Laurent JJ, Webb KM, Beres EJ et al.: The use of bone morphogenetic protein-6 gene therapy for percutaneous spinal fusion in rabbits. J. Neurosurg. Spine 1, 90-94 (2004).
59. Bright C, Park YS, Sieber AN, Kostuik JP, Leong KW: In vivo evaluation of plasmid DNA encoding OP-1 protein for spine fusion. Spine 31, 2163-2172 (2006).
60. White AP, Vaccaro AR, Hall JA et al.: Clinical applications of BMP-7/OP-1 in fractures, nonunions and spinal fusion. Int. Orthop. 31, 735-741 (2007).
61. Guizzardi S, Di Silvestre M, Scandroglio R, Ruggeri A, Savini R: Implants of heterologous demineralized bone matrix for induction of posterior spinal fusion in rats. Spine 17, 701-707 (1992).
62. Choi Y, Oldenburg FP, Sage L, Johnstone B, Yoo JU: A bridging demineralized bone implant facilitates posterolateral lumbar fusion in New Zealand white rabbits. Spine 32, 36-41 (2007).
63. Vaccaro AR, Stubbs HA, Block JE: Demineralized bone matrix composite grafting for posterolateral spinal fusion. Orthopedics 30, 567-570 (2007).
64. Schizas C, Triantafyllopoulos D, Kosmopoulos V, Tzinieris N, Stafylas K: Posterolateral lumbar spine fusion using a novel demineralized bone matrix: a controlled case pilot study. Arch. Orthop. Trauma. Surg. 128, 621-625 (2008).
65. Gazdag AR, Lane JM, Glaser D, Forster RA: Alternatives to autogenous bone graft: efficacy and indications. J. Am. Acad. Orthop. Surg. 3, 1-8 (1995).
66. Hollinger JO, Brekke J, Gruskin E, Lee D: Role of bone substitutes. Clin. Orthop. 324, 55-65 (1996).
67. Jarcho M: Calcium phosphate ceramics as hard tissue prosthetics. Clin. Orthop. 157, 259-278 (1981).
68. Cinotti G, Patti AM, Vulcano A et al.: Experimental posterolateral spinal fusion with porous ceramics and mesenchymal stem cells. J. Bone Joint. Surg. Br. 86, 135-142 (2004).
69. Barnes B, Boden SD, Louis-Ugbo J et al.: Lower dose of rhBMP-2 achieves spine fusion when combined with an osteoconductive bulking agent in non-human primates. Spine 30, 1127-1133 (2005).
70. Morisue H, Matsumoto M, Chiba K et al.: A novel hydroxyapatite fiber mesh as a carrier for recombinant human bone morphogenetic protein-2 enhances bone union in rat posterolateral fusion model. Spine 31, 1194-1200 (2006).
71. Glassman SD, Dimar JR, Carreon LY et al.: Initial fusion rates with recombinant human bone morphogenetic protein-2/compression resistant matrix and a hydroxyapatite and tricalcium phosphate/collagen carrier in posterolateral spinal fusion. Spine 30, 1694-1698 (2005).
72. Dumont RJ, Dayoub H, Li JZ et al.: Ex vivo bone morphogenetic protein-9 gene therapy using human mesenchymal stem cells induces spinal fusion in rodents. Neurosurgery 51, 1239-1244 (2002).
73. Wang JC, Kanim LE, Yoo S et al.: Effect of regional gene therapy with bone morphogenetic protein-2-producing bone marrow cells on spinal fusion in rats. J. Bone Joint. Surg. Am. 85-A, 905-911 (2003).
74. Peterson B, Iglesias R, Zhang J, Wang JC, Lieberman JR: Genetically modified human derived bone marrow cells for posterolateral lumbar spine fusion in athymic rats: beyond conventional autologous bone grafting. Spine 30, 283-289 (2005).
75. Hasharoni A, Zilberman Y, Turgeman G et al.: Murine spinal fusion induced by engineered mesenchymal stem cells that conditionally express bone morphogenetic protein-2. J. Neurosurg. Spine 3, 47-52 (2005).
76. Hsu WK, Wang JC, Liu NQ et al.: Stem cells from human fat as cellular delivery vehicles in an athymic rat posterolateral spine fusion model. J. Bone Joint. Surg. Am. 90, 1043-1052 (2008).
77. Miyazaki M, Zuk PA, Zou J et al.: Comparison of human mesenchymal stem cells derived from adipose tissue and bone marrow for ex vivo gene therapy in rat spinal fusion model. Spine 33, 863-869 (2008a).
78. Miyazaki M, Sugiyama O, Zou J et al.: Comparison of lentiviral and adenoviral gene therapy for spinal fusion in rats. Spine 33, 1410-1417 (2008).
79. Moutsatsos IK, Turgeman G, Zhou S et al.: Exogenously regulated stem cell-mediated gene therapy for bone regeneration. Mol. Ther. 3, 449-461 (2001).
80. Rubio D, Garcia-Castro J, Martin MC et al.: Spontaneous human adult stem cell transformation. Cancer Res. 65, 3035-3039 (2005).
81. Alden TD, Hankins GR, Beres EJ, Kallmes DF, DF, Helm GA: Bone morphogenetic protein gene therapy for the induction of spinal arthrodesis. Neurosurg. Focus. 4, e12 (1998).
82. Zhao J, Zhao DY, Shen AG et al.: Promoting lumbar spinal fusion by adenovirus-mediated bone morphogenetic protein-4 gene therapy. Chin. J. Traumatol. 10, 72-76 (2007).
83. Bruder JT, Kovesdi I: Adenovirus infection stimulates the Raf/MAPK signaling pathway and indices interleukin-8 expression. J. Virol. 71, 398-340 (1997).
84. Lieber A, He CY, Meuse L et al.: The role of Kupffer cell activation and viral gene expression in early liver toxicity after infusion of recombinant adenovirus vectors. J. Virol. 71, 8798-8807 (1997).
85. Muruve DA, Barnes MJ, Stillman IE, Libermann TA: Adenoviral gene therapy leads to rapid induction of multiple chemokines and acute neutrophil-dependent hepatic injury in vivo. Hum. Gene Ther. 10, 965-976 (1999).
86. Shifrin AL, Chirmule N, Gao GP, Wilson JM, Raper SE: Innate immune responses to adenoviral vector-mediated acute pancreatitis. Pancreas 30, 122-129 (2005).
87. Hamm A, Krott N, Breibach I, Blindt R, Bosserhoff AK: Efficient transfection method for primary cells. Tissue Eng. 8, 235-245 (2002).
88. Aslan H, Zilberman Y, Arbeli V et al.: Nucleofection-based ex vivo nonviral gene delivery to human stem cells as a platform for tissue regeneration. Tissue Eng. 12, 877-889 (2006).
89. Aluigi M, Fogli M, Curti A et al.: Nucleofection is an efficient nonviral transfection technique for human bone marrow-derived mesenchymal stem cells. Stem Cells 24, 454-461 (2006).
90. Lee TC, Ho JT, Hung KS et al.: Bone morphogenetic protein gene therapy using a fibrin scaffold for a rabbit spinal-fusion experiment. Neurosurgery 58, 373-380 (2006).
91. Patel VV, Zhao L, Wong P et al.: An in vitro and in vivo analysis of fibrin glue use to control bone morphogenetic protein diffusion and bone morphogenetic protein-stimulated bone growth. Spine J. 6, 397-403 (2006).